19 research outputs found
Associació de l'estat mutacional de JAK2 i les anomalies citogenètiques en les neoplàsies mieloproliferatives cròniques Filadèlfia negatives : Correlació amb les dades clíniques i analítiques
L'estudi correlaciona l'estat mutacional de JAK2V617F amb les alteracions citogenètiques, algunes dades clíniques i paràmetres de laboratori i valorar l'impacte sobre la progressió i pronòstic de la malaltia de 526 casos de NMPc Ph-. Es conclou que la freqüència d'alteracions citogenètiques, l'esplenomegàlia, els símptomes constitucionals i la progressió són independents de la mutació JAK2V617F, però la majoria de pacients en progressió i cariotip alterat eren JAK2 mutat. Els casos JAK2+ es correlacionen amb les complicacions en el curs de la malaltia i l'augment de la xifra de leucòcits i d'hemoglobina en la TE i de plaquetes en la PV
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. We performed targeted deep sequencing of 83 myeloid-related genes in 56 CMML patients with low risk cytogenetic features or uninformative conventional cytogenetics (CC) at diagnosis, with the aim to identify the genetic characteristics of patients with a more aggressive disease. Targeted sequencing was also performed in a subset of these patients at time of acute myeloid leukemia (AML) transformation. Overall, 98% of patients harbored at least one mutation. Mutations in cell signaling genes were acquired at time of AML progression. Mutations in ASXL1, EZH2 and NRAS correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS). Patients with SRSF2 mutations associated with poorer OS, while absence of TET2 mutations (TET2wt) was predictive of shorter PFS. A decrease in OS and PFS was observed as the number of adverse risk gene mutations (ASXL1, EZH2, NRAS and SRSF2) increased. On multivariate analyses, CMML-specific scoring system (CPSS) and presence of adverse risk gene mutations remained significant for OS, while CPSS and TET2wt were predictive of PFS. These results confirm that mutation analysis can add prognostic value to patients with CMML and low risk cytogenetic features or uninformative CC
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. We performed targeted deep sequencing of 83 myeloid-related genes in 56 CMML patients with low risk cytogenetic features or uninformative conventional cytogenetics (CC) at diagnosis, with the aim to identify the genetic characteristics of patients with a more aggressive disease. Targeted sequencing was also performed in a subset of these patients at time of acute myeloid leukemia (AML) transformation. Overall, 98% of patients harbored at least one mutation. Mutations in cell signaling genes were acquired at time of AML progression. Mutations in ASXL1, EZH2 and NRAS correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS). Patients with SRSF2 mutations associated with poorer OS, while absence of TET2 mutations (TET2 wt) was predictive of shorter PFS. A decrease in OS and PFS was observed as the number of adverse risk gene mutations (ASXL1, EZH2, NRAS and SRSF2) increased. On multivariate analyses, CMML-specific scoring system (CPSS) and presence of adverse risk gene mutations remained significant for OS, while CPSS and TET2wt were predictive of PFS. These results confirm that mutation analysis can add prognostic value to patients with CMML and low risk cytogenetic features or uninformative CC
Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia
Linfoma de Hodgkin en paciente con enfermedad de Crohn tratada con azatioprina y anticuerpos antifactor de necrosis tumoral α
Associació de l'estat mutacional de JAK2 i les anomalies citogenètiques en les neoplàsies mieloproliferatives cròniques Filadèlfia negatives : Correlació amb les dades clíniques i analítiques
L'estudi correlaciona l'estat mutacional de JAK2V617F amb les alteracions citogenètiques, algunes dades clíniques i paràmetres de laboratori i valorar l'impacte sobre la progressió i pronòstic de la malaltia de 526 casos de NMPc Ph-. Es conclou que la freqüència d'alteracions citogenètiques, l'esplenomegàlia, els símptomes constitucionals i la progressió són independents de la mutació JAK2V617F, però la majoria de pacients en progressió i cariotip alterat eren JAK2 mutat. Els casos JAK2+ es correlacionen amb les complicacions en el curs de la malaltia i l'augment de la xifra de leucòcits i d'hemoglobina en la TE i de plaquetes en la PV